BTLA

BTLA or B and T Lymphocyte Attenuator is a protein that in humans is encoded by the BTLA gene. BTLA is a member of the immunoglobulin superfamily and is expressed on T-lymphocytes, B-lymphocytes, and other immune cells. It functions as an immune checkpoint and plays a crucial role in the regulation of immune responses.

Structure

BTLA is a type I transmembrane protein with an extracellular immunoglobulin domain. The extracellular domain of BTLA interacts with its ligand, herpesvirus entry mediator (HVEM), a member of the tumor necrosis factor receptor superfamily.

Function

BTLA serves as a negative regulator of the immune response. Upon binding to HVEM, BTLA inhibits T-cell activation, proliferation, and cytokine production, thereby preventing excessive immune responses and maintaining immune homeostasis. BTLA also plays a role in the development and function of regulatory T cells, which further contributes to immune regulation.

Clinical significance

Alterations in the BTLA-HVEM pathway have been implicated in various diseases, including autoimmune diseases, infectious diseases, and cancer. In cancer, BTLA is often upregulated on tumor-infiltrating lymphocytes, and its interaction with HVEM can contribute to immune evasion by the tumor. Therefore, targeting the BTLA-HVEM pathway is being explored as a potential strategy for cancer immunotherapy.

See also

• Immune checkpoint
• Tumor necrosis factor receptor
• Regulatory T cell

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian